Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$11,793 Mln
P/E Ratio
15.23
P/B Ratio
1.23
Industry P/E
--
Debt to Equity
0.37
ROE
0.08 %
ROCE
6.03 %
Div. Yield
0 %
Book Value
115.8
EPS
9.62
CFO
$4,582.19 Mln
EBITDA
$6,817.54 Mln
Net Profit
$3,242.57 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
ICON - ADR
| -28.80 | -16.62 | -26.15 | -51.57 | -12.78 | -0.43 | 8.78 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
ICON - ADR
| 45.72 | -37.28 | 58.84 | 13.21 | 33.29 | 15.12 | 49.14 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development,... management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland. Read more
Founder & Independent Non-Executive Director
Dr. John Climax Ph.D.
Founder & Independent Non-Executive Director
Dr. John Climax Ph.D.
Headquarters
Dublin
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of ICON plc - ADR stood at $ 16,878 Mln as on 31-Dec-24
The share price of ICON plc - ADR is $149.31 (NASDAQ) as of 29-Apr-2025 16:00 EDT. ICON plc - ADR has given a return of -12.78% in the last 3 years.
ICON plc - ADR has a market capitalisation of $ 11,793 Mln as on 25-Apr-2025. As per Value Research classification, it is a company.
The P/E ratio of ICON plc - ADR is 15.23 times as on 25-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ICON plc - ADR and enter the required number of quantities and click on buy to purchase the shares of ICON plc - ADR.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
The CEO & director of Dr. John Climax Ph.D.. is ICON plc - ADR, and CFO & Sr. VP is Dr. John Climax Ph.D..
There is no promoter pledging in ICON plc - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| ICON plc - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
8.44
|
|
Operating margin(%)
|
13.36
|
|
Net Margin(%)
|
9.56
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of ICON plc - ADR was $791 Mln.
$4.31
(
